Recently diagnosed with HIV? Click here

Predictors of drug hypersensitivity

Clinical trial • Enrolling • 11 May 2007
This trial is enrolling now. Depending on eligibility and available places in your area, you may be able to enrol in this trial.

About this trial

This study will compare people who are hypersensitive to three particular drugs with people who are not. The three drugs - nevirapine, efavirenz and abacavir - are all known to cause hypersensitivity reactions in a small number of people and so the study is looking for particular immune system markers which might predict who can safely take them and who might have reactions to them.

This is an observational study. There is no experimental(Of a drug) Not licensed for use in humans, or as a treatment for a particular condition. Experimental drugs are studied in clinical trials to determine their safety and efficacy, and are sometimes made available via Special Access Schemes prior to their approval. treatment associated with this trial.

Background information

"Hypersensitivity" refers to an immune reaction to a drug, which usually prevents a person from being able to safely use it. Symptoms can include rash, blisters or breathing problems.

Official title:Predictors of Drug Hypersensitivity in HIV-infected subjects
What is this trial studying?Side effect management
Start date:August 2005

This may be the proposed or expected start date for trials which have not yet started.

How many participants will this trial enrol?800

The exact number of participants may be lower or slightly higher than this. Some trials also have specific quotas for participants from each state, city or clinic.

Links to further information:
Can I access this treatment other than by enrolling in this trial?

All drugs are licensed in Australia and available through the PBS[Pharmaceutical Benefits Scheme] The federal government program which subsidises medication costs in Australia. Anti-HIV drugs are part of a special part of the PBS called Section 100 (S100) which is used for expensive, highly specialised drugs..

Tags:hypersensitivity reactions

Who can enrol in this trial?

You may be eligible to participate in this trial if you meet the following criteria:

  • At least 18 years old
  • Have taken HIV treatments in the past
  • Currently taking abacavir, nevirapine or efavirenz.

This is a summary of key inclusion and exclusion criteria for this trial. There may be other criteria which may exclude some people from participation in this trial. Some laboratory tests may also be required. Consult your doctor, or view the trial protocol or informed consent documentation to see the full range of exclusion and inclusion criteria.

If you are interested in enrolling in this trial

Before making the decision to participate in any clinical trial, NAPWA recommends that you discuss the potential benefits and risks of participation with your treating doctor. Your doctor can also provide advice about your eligibility to participate in the trial.

While NAPWA has taken every care to compile the information on this page and to keep it up-to-date, we cannot guarantee its correctness and completeness.

  • You can print this page to take it with you to the doctor – just use your browser's 'print' function.
  • Before making the decision to participate in any clinical research, read our background information.
  • Email NAPWA if you have any questions or comments about this trial
Text size: font smallerfont normalfont larger print-friendly version of this pagePDF version of this pageemail this page to a friend

This Clinical trial was first published on 11 May 2007 — more than five years ago.

While the content of this clinical trial was checked for accuracy at the time of publication, NAPWA recommends checking to determine whether the information is the most up-to-date available, especially when making decisions which may affect your health.

This article may contain medical information. NAPWA makes every reasonable effort to ensure the information on this website is accurate, reliable and up-to-date, including obtaining technical reviews by medically-qualified reviewers, however the authors of information on this website are not qualified to give medical advice, except where explicitly stated.

The content of this website is intended to support, not replace, the relationship between people living with HIV/AIDS and their medical advisers, and is not intended as a substitute for medical advice.

Website links

HIV Clinical Trials update

Recently updated entries from the NAPWA Clinical Trials database.

more